Recent reports emphasize that dRTA in pSS may be underdiagnosed, and atypical mechanisms (e.g., AE1 dysfunction) have been described, reinforcing the need for targeted immunosuppression alongside electrolyte and alkali therapy [3,6,9]. This evidence concerns the gene SLC4A1 and peeling skin syndrome.